On page 2680, in Figure 2C, a panel of mouse images is shown more than once (day 1 scr and day 16 Pyk2 K.D.), and some panels are mislabeled (the images in the first 2 rows of the day 26 column are actually from day 22). The authors have provided the original files with the correct mouse images and labels. Among the original files reviewed by the Blood editors were results for day 22 of the experiment. At the editors’ request, the authors have added these results to the figure, as well as a statement in the figure legend explaining why 1 mouse was excluded from analysis. These figure assembly errors do not affect the results or the conclusions of the study. The corrected Figure 2C and the updated portion of the figure legend describing it are shown below.
Pyk2 silencing decreases MM tumor growth in a mouse xenograft model. (C) SCID/Beige mice were injected IV with GFP+/Luc+-MM.1S Pyk2-knockdown (A4) or FAK-knockdown cells (3 × 106/mouse) to establish an MM xenograft model (n = 5 per group). Tumor burden was detected and quantified using BLI. Inhibition of Pyk2 significantly reduced MM tumor burden compared with scramble control. One mouse in the day 26 FAK-K.D. image was excluded from the analysis due to poor IV injection of luciferin for that mouse.
Pyk2 silencing decreases MM tumor growth in a mouse xenograft model. (C) SCID/Beige mice were injected IV with GFP+/Luc+-MM.1S Pyk2-knockdown (A4) or FAK-knockdown cells (3 × 106/mouse) to establish an MM xenograft model (n = 5 per group). Tumor burden was detected and quantified using BLI. Inhibition of Pyk2 significantly reduced MM tumor burden compared with scramble control. One mouse in the day 26 FAK-K.D. image was excluded from the analysis due to poor IV injection of luciferin for that mouse.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal